Literature DB >> 16878130

Regulation of MLL1 H3K4 methyltransferase activity by its core components.

Yali Dou1, Thomas A Milne, Alexander J Ruthenburg, Seunghee Lee, Jae Woon Lee, Gregory L Verdine, C David Allis, Robert G Roeder.   

Abstract

Histone H3 Lys4 (H3K4) methylation is a prevalent mark associated with transcription activation. A common feature of several H3K4 methyltransferase complexes is the presence of three structural components (RbBP5, Ash2L and WDR5) and a catalytic subunit containing a SET domain. Here we report the first biochemical reconstitution of a functional four-component mixed-lineage leukemia protein-1 (MLL1) core complex. This reconstitution, combined with in vivo assays, allows direct analysis of the contribution of each component to MLL1 enzymatic activity and their roles in transcriptional regulation. Moreover, taking clues from a crystal structure analysis, we demonstrate that WDR5 mediates interactions of the MLL1 catalytic unit both with the common structural platform and with the histone substrate. Mechanistic insights gained from this study can be generalized to the whole family of SET1-like histone methyltransferases in mammals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16878130     DOI: 10.1038/nsmb1128

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  390 in total

Review 1.  Polycomb and Trithorax Group Genes in Drosophila.

Authors:  Judith A Kassis; James A Kennison; John W Tamkun
Journal:  Genetics       Date:  2017-08       Impact factor: 4.562

2.  Structural basis for WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases.

Authors:  Venkatasubramanian Dharmarajan; Jeong-Heon Lee; Anamika Patel; David G Skalnik; Michael S Cosgrove
Journal:  J Biol Chem       Date:  2012-06-03       Impact factor: 5.157

3.  Charge-based interaction conserved within histone H3 lysine 4 (H3K4) methyltransferase complexes is needed for protein stability, histone methylation, and gene expression.

Authors:  Douglas P Mersman; Hai-Ning Du; Ian M Fingerman; Paul F South; Scott D Briggs
Journal:  J Biol Chem       Date:  2011-12-06       Impact factor: 5.157

4.  Structure of the SPRY domain of human Ash2L and its interactions with RbBP5 and DPY30.

Authors:  Yong Chen; Fang Cao; Bingbing Wan; Yali Dou; Ming Lei
Journal:  Cell Res       Date:  2012-01-10       Impact factor: 25.617

5.  Structural analysis of the core COMPASS family of histone H3K4 methylases from yeast to human.

Authors:  Yoh-hei Takahashi; Gerwin H Westfield; Austin N Oleskie; Raymond C Trievel; Ali Shilatifard; Georgios Skiniotis
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-07       Impact factor: 11.205

Review 6.  Role of histone methylation and demethylation in adipogenesis and obesity.

Authors:  Masashi Okamura; Takeshi Inagaki; Toshiya Tanaka; Juro Sakai
Journal:  Organogenesis       Date:  2010 Jan-Mar       Impact factor: 2.500

7.  Wdr82 is a C-terminal domain-binding protein that recruits the Setd1A Histone H3-Lys4 methyltransferase complex to transcription start sites of transcribed human genes.

Authors:  Jeong-Heon Lee; David G Skalnik
Journal:  Mol Cell Biol       Date:  2007-11-12       Impact factor: 4.272

8.  H3K4 methyltransferase Set1 is involved in maintenance of ergosterol homeostasis and resistance to Brefeldin A.

Authors:  Paul F South; Kayla M Harmeyer; Nina D Serratore; Scott D Briggs
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

9.  Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents.

Authors:  Cecily A Bennett; Amanda C Winters; Nisha N Barretto; Charles S Hemenway
Journal:  Leuk Res       Date:  2009-02-20       Impact factor: 3.156

Review 10.  Menin, histone h3 methyltransferases, and regulation of cell proliferation: current knowledge and perspective.

Authors:  Xinjiang Wu; Xianxin Hua
Journal:  Curr Mol Med       Date:  2008-12       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.